Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma.
immune checkpoint inhibitors
selective internal radiation therapy
uveal melanoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Feb 2022
24 Feb 2022
Historique:
received:
10
01
2022
revised:
21
02
2022
accepted:
22
02
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
11
3
2022
Statut:
epublish
Résumé
To assess the safety and efficacy of ipilimumab plus nivolumab around selective internal radiation therapy (SIRT) in patients with metastatic uveal melanoma (mUM). We present a retrospective, single center study of 32 patients with mUM divided into two groups based on the treatment received between April 2013 and April 2021. The SIRT_IpiNivo cohort was treated with Yttrium-90 microspheres and ipilimumab plus nivolumab before or after the SIRT (
Identifiants
pubmed: 35267470
pii: cancers14051162
doi: 10.3390/cancers14051162
pmc: PMC8909598
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Mol Cancer Ther. 2020 Apr;19(4):1031-1039
pubmed: 32029634
Ann Oncol. 2013 Nov;24(11):2911-5
pubmed: 24067719
Cancer Cell. 2017 Aug 14;32(2):204-220.e15
pubmed: 28810145
J Vasc Interv Radiol. 2018 Oct;29(10):1369-1375
pubmed: 30174161
Cardiovasc Intervent Radiol. 2013 Feb;36(1):158-65
pubmed: 22526099
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
N Engl J Med. 2021 Sep 23;385(13):1196-1206
pubmed: 34551229
Cancers (Basel). 2019 Jun 18;11(6):
pubmed: 31216772
Ann Oncol. 2014 Mar;25(3):742-746
pubmed: 24510314
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153
Cancer Med. 2013 Oct;2(5):674-86
pubmed: 24403233
Ophthalmology. 2007 Dec;114(12):2309-15
pubmed: 17498805
Cancer Chemother Pharmacol. 2019 Jul;84(1):15-32
pubmed: 31079217
Eur J Surg Oncol. 2009 Nov;35(11):1192-7
pubmed: 19329272
Cancer Discov. 2013 Oct;3(10):1122-1129
pubmed: 23861464
Cancer. 2016 Nov 15;122(21):3344-3353
pubmed: 27533448
J Vasc Interv Radiol. 2006 Sep;17(9):1425-39
pubmed: 16990462
JAMA. 2014 Jun 18;311(23):2397-405
pubmed: 24938562
Cardiovasc Intervent Radiol. 2015 Aug;38(4):794-805
pubmed: 25828724
Arch Ophthalmol. 2005 Dec;123(12):1639-43
pubmed: 16344433
Ther Adv Med Oncol. 2018 Feb 21;10:1758834018757175
pubmed: 29497459
Arch Ophthalmol. 2009 Aug;127(8):989-98
pubmed: 19667335
Acta Radiol Open. 2015 Apr 06;4(4):2047981615570417
pubmed: 25922690
Eur J Cancer. 2017 Sep;82:56-65
pubmed: 28648699
Invest Ophthalmol Vis Sci. 2006 Jan;47(1):3-6
pubmed: 16384937
Cancers (Basel). 2021 Dec 20;13(24):
pubmed: 34945010
HPB (Oxford). 2020 Apr;22(4):497-505
pubmed: 31791894
J Clin Oncol. 2021 Feb 20;39(6):586-598
pubmed: 33417511
JAMA Ophthalmol. 2018 Sep 1;136(9):981-986
pubmed: 29955797
J Clin Oncol. 2018 Apr 20;36(12):1232-1239
pubmed: 29528792
Cardiovasc Intervent Radiol. 2020 Feb;43(2):254-263
pubmed: 31686137
Melanoma Res. 2016 Jun;26(3):272-7
pubmed: 26795274
AJR Am J Roentgenol. 2011 Feb;196(2):468-73
pubmed: 21257902
Ann Oncol. 2006 Dec;17(12):1826-9
pubmed: 16971664
Melanoma Res. 2013 Jun;23(3):196-8
pubmed: 23624366
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
J Vasc Interv Radiol. 2020 Aug;31(8):1233-1241
pubmed: 32741550
Br J Ophthalmol. 2021 Jan 15;:
pubmed: 33452185
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32581057
Ophthalmology. 1991 Mar;98(3):383-9; discussion 390
pubmed: 2023760
Acta Oncol. 2018 Oct;57(10):1373-1380
pubmed: 29683787
Am J Clin Oncol. 2017 Feb;40(1):27-34
pubmed: 25089529
CA Cancer J Clin. 2017 Jan;67(1):65-85
pubmed: 27570942
Cancer Discov. 2021 Aug;11(8):1938-1951
pubmed: 33811047
Radiology. 2019 Oct;293(1):223-231
pubmed: 31453767
J Clin Oncol. 2021 Feb 20;39(6):599-607
pubmed: 33125309
Cancer. 2013 Oct 15;119(20):3687-95
pubmed: 23913718
Am J Clin Oncol. 2016 Apr;39(2):189-95
pubmed: 24441583
J Nucl Med. 2020 Mar;61(3):350-356
pubmed: 31481579
J Immunother Cancer. 2019 Nov 13;7(1):299
pubmed: 31722735